Rosetta Genomics (ROSGQ) Stock Price
Rosetta Genomics Price
Revenue has compounded at 25.4% per year over the past 8 years to 9.23 M USD. Rosetta Genomics's net margin stands at -175.8%, up from -5,202.5% several years earlier. The stock trades about 100% above its 52-week low.
Rosetta Genomics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Rosetta Genomics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Rosetta Genomics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Rosetta Genomics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Rosetta Genomics Price |
|---|---|
| 8/7/2026 | 0.00 USD |
| 8/6/2026 | 0.00 USD |
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
| 7/21/2026 | 0.00 USD |
| 7/20/2026 | 0.00 USD |
| 7/17/2026 | 0.00 USD |
| 7/16/2026 | 0.00 USD |
| 7/15/2026 | 0.00 USD |
| 7/14/2026 | 0.00 USD |
| 7/13/2026 | 0.00 USD |
| 7/10/2026 | 0.00 USD |
| 7/9/2026 | 0.00 USD |
| 7/8/2026 | 0.00 USD |
| 7/7/2026 | 0.00 USD |
| 7/6/2026 | 0.00 USD |
| 7/2/2026 | 0.00 USD |
| 7/1/2026 | 0.00 USD |
| 6/30/2026 | 0.00 USD |
| 6/29/2026 | 0.00 USD |
| 6/26/2026 | 0.00 USD |
| 6/25/2026 | 0.00 USD |
| 6/24/2026 | 0.00 USD |
| 6/23/2026 | 0.00 USD |
| 6/22/2026 | 0.00 USD |
| 6/18/2026 | 0.00 USD |
| 6/17/2026 | 0.00 USD |
| 6/16/2026 | 0.00 USD |
| 6/15/2026 | 0.00 USD |
| 6/12/2026 | 0.00 USD |
| 6/11/2026 | 0.00 USD |
| 6/10/2026 | 0.00 USD |
| 6/9/2026 | 0.00 USD |
| 6/8/2026 | 0.00 USD |
| 6/5/2026 | 0.00 USD |
| 6/4/2026 | 0.00 USD |
| 6/3/2026 | 0.00 USD |
| 6/2/2026 | 0.00 USD |
| 6/1/2026 | 0.00 USD |
| 5/29/2026 | 0.00 USD |
| 5/28/2026 | 0.00 USD |
| 5/27/2026 | 0.00 USD |
| 5/26/2026 | 0.00 USD |
| 5/22/2026 | 0.00 USD |
| 5/21/2026 | 0.00 USD |
| 5/20/2026 | 0.00 USD |
| 5/19/2026 | 0.00 USD |
| 5/18/2026 | 0.00 USD |
| 5/15/2026 | 0.00 USD |
| 5/14/2026 | 0.00 USD |
| 5/13/2026 | 0.00 USD |
| 5/12/2026 | 0.00 USD |
| 5/11/2026 | 0.00 USD |
| 3/13/2026 | 0.00 USD |
| 3/3/2026 | 0.00 USD |
| 2/20/2026 | 0.00 USD |
| 2/19/2026 | 0.00 USD |
| 1/7/2026 | 0.00 USD |
| 11/12/2025 | 0.00 USD |
| 11/7/2025 | 0.00 USD |
| 11/3/2025 | 0.00 USD |
| 10/27/2025 | 0.00 USD |
| 10/20/2025 | 0.00 USD |
| 10/17/2025 | 0.00 USD |
| 10/14/2025 | 0.00 USD |
| 9/23/2025 | 0.00 USD |
| 9/19/2025 | 0.00 USD |
| 8/25/2025 | 0.00 USD |
| 8/21/2025 | 0.00 USD |
| 8/20/2025 | 0.00 USD |
| 8/15/2025 | 0.00 USD |
| 8/14/2025 | 0.00 USD |
Rosetta Genomics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Rosetta Genomics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017e | 2018e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | 1.00 | – | – | – | – | – | 1.00 | 8.00 | 9.00 | 20.00 | 39.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | 700.00 | 12.50 | 122.22 | 95.00 |
| – | – | – | – | – | 100.00 | – | – | – | – | – | 100.00 | 12.50 | 11.11 | 11.11 | 11.11 |
| 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.22 | 4.33 |
| -2.00 | -2.00 | -5.00 | -8.00 | -11.00 | -14.00 | -14.00 | -15.00 | -8.00 | -8.00 | -13.00 | -14.00 | -15.00 | -15.00 | -14.00 | -15.00 |
| – | – | – | – | – | -1,400.00 | – | – | – | – | – | -1,400.00 | -187.50 | -166.67 | -70.00 | -38.46 |
| -2.00 | -2.00 | -5.00 | -7.00 | -14.00 | -9.00 | -16.00 | -14.00 | -8.00 | -10.00 | -12.00 | -14.00 | -17.00 | -16.00 | -19.00 | -25.00 |
| – | – | 150.00 | 40.00 | 100.00 | -35.71 | 77.78 | -12.50 | -42.86 | 25.00 | 20.00 | 16.67 | 21.43 | -5.88 | 18.75 | 31.58 |
| 1.74 | 1.74 | 1.74 | 1.74 | 0.02 | 0.02 | 0.02 | 0.02 | 0.63 | 0.63 | 0.80 | 0.94 | 1.26 | 1.74 | 1.74 | 1.74 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Rosetta Genomics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Rosetta Genomics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Rosetta Genomics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Rosetta Genomics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Rosetta Genomics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Rosetta Genomics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Rosetta Genomics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Rosetta Genomics business model & stock analysis
Rosetta Genomics SWOT Analysis
Strengths
- Advanced technology and proprietary algorithms for molecular diagnostics.
- Strong patent portfolio providing a competitive advantage in the industry.
- Well-established relationships with key partners and collaborators.
- Robust financial position with steady revenue growth in recent years.
Weaknesses
- Relatively small market share compared to larger competitors.
- Dependence on a limited number of key customers for a significant portion of revenue.
- Limited marketing and brand presence, especially among the general public.
- High research and development costs impacting short-term profitability.
Opportunities
- Increasing demand for personalized medicine and targeted therapies.
- Growing awareness and adoption of molecular diagnostics in healthcare industry.
- Opportunities for strategic partnerships or collaborations to expand market reach.
- Potential for regulatory changes favoring the use of molecular diagnostics.
Threats
- Intense competition from larger and well-established players in the industry.
- Changing regulatory landscape and potential impact on market access.
- Rapid technological advancements making previous technologies outdated.
- Potential for economic downturn affecting overall healthcare spending.
Rosetta Genomics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Rosetta Genomics historical P/E ratio, EBIT multiple, and P/S ratio
Rosetta Genomics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Rosetta Genomics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Rosetta Genomics stock splits
Rosetta Genomics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 3/30/2017 | -1.42USD | - | 2.81 MUSD | - | 2016 Q4 |
| 12/20/2016 | -2.04USD | - | 2.65 MUSD | - | 2016 Q3 |
| 9/26/2016 | -2.14USD | - | 3.05 MUSD | - | 2016 Q2 |
| 5/19/2016 | -1.98USD | - | 3.41 MUSD | - | 2016 Q1 |
| 3/23/2016 | -2.47USD | - | 3.04 MUSD | - | 2015 Q4 |
| 9/17/2014 | -8.28USD | - | -USD | - | 2014 Q2 |
| 11/30/2010 | -166.86USD | - | 173,564.00USD | - | 2010 Q3 |
| 9/7/2010 | -138.43USD | - | 260,854.00USD | - | 2010 Q2 |
| 5/26/2010 | -144.61USD | - | 603,417.00USD | - | 2010 Q1 |
| 3/31/2010 | -174.28USD | - | 85,767.00USD | - | 2009 Q4 |
Rosetta Genomics shareholder structure
| % | Name |
|---|---|
0.00000% |
Rosetta Genomics Executives and Management Board
10 members · avg. age 56 · 40 % women
Mr. Ron Kalfus (41)
Chief Financial Officer
262,785.00 USD
Management
Dr. Dganit Bar (47)
Chief Scientific Officer
Dr. Eti Meiri (47)
Vice President - Research
Board of Directors
Mr. Brian Markison (65)
Independent Chairman of the Board
Ms. Sigal Russo-Gueta (38)
Senior Director Of Finance
Mr. Roy Davis (69)
Director
Mr. Gerald Dogon (76)
External Independent Director
Dr. Joshua Rosensweig
Independent Director
Dr. David Sidransky (65)
Independent Director
Frequently asked questions about Rosetta Genomics
Rosetta Genomics Ltd operates as a molecular diagnostics company that develops and commercializes diagnostic tests and therapeutic tools. The company focuses on the identification and validation of novel microRNA biomarkers for various diseases, including cancer. Rosetta Genomics employs advanced technologies to analyze gene expression profiles to provide accurate and reliable diagnostic information. By utilizing its proprietary microRNA platform, the company aims to improve patient care and enable personalized medicine. Rosetta Genomics' business model centers around offering innovative molecular diagnostic tests to healthcare professionals and partnering with pharmaceutical companies for therapeutic development.
Rosetta Genomics Ltd is primarily active in the biotechnology industry.
The main competitors of Rosetta Genomics Ltd in the market include companies like Veracyte, Inc., Guardant Health, Inc., and Exact Sciences Corporation.
Rosetta Genomics Ltd, founded in 2000, is a leading molecular diagnostics company specializing in developing and commercializing innovative diagnostic tests. Headquartered in Israel, the company focuses on personalized medicine and offers a range of diagnostic products for the detection of various diseases. With a strong emphasis on microRNA technology, Rosetta Genomics has developed proprietary algorithms and bioinformatics tools that facilitate accurate diagnostic testing. The company has received numerous approvals and certifications for its products, enabling healthcare professionals to make informed treatment decisions. Rosetta Genomics Ltd is dedicated to advancing precision medicine through its cutting-edge technologies and commitment to improving patient outcomes.
Rosetta Genomics Ltd, a leading genomics company, has achieved several significant milestones. This include obtaining regulatory approval for their groundbreaking diagnostic tests, securing strategic partnerships with reputable pharmaceutical companies, and achieving key milestones in the development of personalized medicine. Furthermore, the company has successfully commercialized innovative genomic products, expanding its market reach globally. Rosetta Genomics Ltd's dedication to advancing genomics research and personalized medicine has positioned it as a prominent player in the industry. With its dynamic accomplishments, Rosetta Genomics Ltd continues to revolutionize the field of genomics and improve patient outcomes.
Rosetta Genomics Ltd primarily operates in the United States and Israel.
Rosetta Genomics Ltd represents a commitment to precision medicine and cutting-edge genomic solutions. With an emphasis on personalized diagnosis and treatment, the company aims to revolutionize healthcare by leveraging its advanced microRNA-based technologies. Rosetta Genomics embraces a patient-centric approach, delivering accurate and actionable information to facilitate better treatment decisions. Continually pushing boundaries in the field of molecular diagnostics, the company strives to improve patient outcomes and enhance therapeutic options. Through innovation, expertise, and a dedication to improving lives, Rosetta Genomics remains at the forefront of molecular profiling, empowering healthcare professionals with valuable insights for effective disease management.
9 analysts currently rate the Rosetta Genomics stock: 8 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Rosetta Genomics share trades at 0.00 EUR (0.00 USD).
Rosetta Genomics Ltd is a company specializing in oncology, whose business model is based on the development and marketing of diagnostic tests, therapies, and tools for cancer research. The company is divided into three main business areas: molecular diagnostics, personalized medicine, and research. All three areas are closely interconnected and contribute to the development of innovative products. Molecular diagnostics involves the development of diagnostic tests specifically targeting cancer types such as lung, breast, stomach, colon, liver, pancreatic, and thyroid cancer. Rosetta Genomics utilizes state-of-the-art technologies like Next-Generation Sequencing and qPCR to develop these tests. Personalized medicine aims to personalize and improve the treatment of cancer patients. Rosetta Genomics offers high-throughput personalized therapies and diagnostic tests based on the analysis of biomarkers such as miRNA, mRNA, and gene expression profiles. These tests enable physicians to plan more precise and effective treatments. The company's research division develops its own products and technologies for cancer research. Rosetta Genomics offers research tools that enable the identification of new biomarkers, the development of prognostic tests, and the exploration of new therapeutic approaches. Rosetta Genomics has a wide range of products on the market, including the miRview® test, which allows for rapid and reliable diagnosis of lung, colon, and pancreatic cancer. The on-site miRview® Mets test enables precise determination of the origin of metastasized tumors. Key products also include the MSK-CC Panel and the IBD-CC Panel, both widely used in the research community for their quick results and high accuracy. In summary, Rosetta Genomics' business model is focused on the development and marketing of innovative diagnostic tests, personalized medicines, and technologies for cancer research. Through the use of cutting-edge technologies, the company is able to offer sophisticated products aimed at more precise diagnosis and treatment of cancer.
The revenue cannot currently be calculated for Rosetta Genomics.
The profit cannot currently be calculated for Rosetta Genomics.
The P/E ratio cannot be calculated for Rosetta Genomics at the moment.
The P/S cannot be calculated for Rosetta Genomics currently.
The Eulerpool Quality Score for Rosetta Genomics is 4/10.
The ISIN of Rosetta Genomics is IL0011026494. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Rosetta Genomics is A0MMDG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Rosetta Genomics is ROSGQ. The ticker symbol is used to trade Rosetta Genomics shares on the stock exchange.
Rosetta Genomics paid dividends every year for the past 0 years.
Rosetta Genomics is assigned to the 'Health' sector.
The dividends of Rosetta Genomics are distributed in USD.
Rosetta Genomics stock
Rosetta Genomics Peer Group
Rosetta Genomics Ticker
Rosetta Genomics FIGI
All fundamentals and in-depth analysis of Rosetta Genomics
Our stock analysis for Rosetta Genomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rosetta Genomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.